

SYSTEMATIC EXCELLENCESM

Flow Cytometry Applications for Isolating and Analyzing Complex Heterogeneous Stem Cell Cultures

Nil Emre, PhD
Manager, Stem Cell Research and Development
BD Biosciences

23-15381-00

For Research Use Only. Not for use in diagnostic or therapeutic procedures.



Overview

- Background
- Immunophenotyping Screens
- Improved Sorting of Pluripotent Stem Cells
- Enrichment for hiPSCs during Reprogramming
- Monitoring Lineage Specification Using Multiparameter Flow Cytometry
- MSC Characterization Using Flow Cytometry

Applications and Challenges in Stem Cell Research

Applications of stem cell research:

- Cell therapy
- In vitro disease models
- Basic research

Heterogeneity of cell cultures is a major challenge.


The field is in need of:


- Defined cell-surface signatures for pluripotent stem cells and their derivatives
- Robust methods for cell sorting
- Quantitative analysis tools for heterogeneous cell cultures

The BD Biosciences Stem Cell Research group in La Jolla, CA is addressing these hurdles:

- Developing antibody-based reagents and applications for flow cytometry and bioimaging technology platforms
- Working with key opinion leaders in technology development

Immunophenotyping Screens for Identifying Cell-Surface Signatures of Human Embryonic Stem Cell (hESC) and Human Induced Pluripotent Stem Cell (hiPSC) Derived NSCs, Neurons, and Glia by Flow Cytometry





Can we use our portfolio of antibodies to cell-surface markers to identify signatures of stem cells and their derivatives outside hematopoiesis?

BD Lyoplate™ Screening Panels

Enabling researchers to immunophenotype cell populations by flow cytometry or immunofluorescence microscopy using BD's portfolio of monoclonal antibodies



- Accelerate the discovery of unique cell-surface “signatures”
- A unique, cost-effective alternative to screening using hundreds of single-vial reagents

Product	Contents	Size
BD Lyoplate™ <i>Human</i> Cell Surface Marker Screening Panel Cat. No. 560747	<ul style="list-style-type: none"> • 242 CD markers* • Isotype controls • Alexa Fluor® 647 second step 	5 tests
BD Lyoplate™ <i>Mouse</i> Cell Surface Marker Screening Panel Cat. No. 562208	<ul style="list-style-type: none"> • 176 CD markers • Isotype controls • Biotin second step • Alexa Fluor® 647 streptavidin third step 	5 tests
*CD and other cell-surface molecules. One marker per well.		

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Stem Cell Research Screening Applications

August 2011, Volume 6, Issue 8



Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression

Hideki Uosaki^{1,2}, Hiroyuki Fukushima^{1,2}, Ayako Takeuchi³, Satoshi Matsuoka⁴, Norio Nakatsuji⁵, Shinya Yamanaka⁶, Jun K. Yamashita^{1,2*}

**nature
biotechnology**

October 2011, Volume 29, Issue 11

SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells

Nicole C Dubois¹, April M Craft¹, Parveen Sharma², David A Elliott³, Edouard G Stanley³, Andrew G Elefanty³, Anthony Gramolini² & Gordon Keller¹

December 2012, Volume 7, Issue 12



Differential Expression of Surface Markers in Mouse Bone Marrow Mesenchymal Stromal Cell Subpopulations with Distinct Lineage Commitment


Maria Rostovskaya, Konstantinos Anastassiadis*

Cell-Surface Marker Signatures for the Isolation of Neural Stem Cells, Glia and Neurons Derived from Human Pluripotent Stem Cells

Shauna H. Yuan^{1,2}, Jody Martin³, Jeanne Elia³, Jessica Flippin¹, Rosanto I. Paramban³, Mike P. Hefferan⁴, Jason G. Vidal³, Yangling Mu⁵, Rhiannon L. Killian^{1,6}, Mason A. Israel^{1,6}, Nil Emre³, Silvia Marsala⁴, Martin Marsala^{4,7}, Fred H. Gage⁵, Lawrence S. B. Goldstein¹, Christian T. Carson^{3*}

1 Howard Hughes Medical Institute and Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, California, United States of America, **2** Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla, California, United States of America, **3** BD Biosciences, La Jolla, California, United States of America, **4** Anesthesiology Research Laboratory, Department of Anesthesiology, University of California San Diego, La Jolla, California, United States of America, **5** Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California, United States of America, **6** Biomedical Sciences Graduate Program, University of California San Diego, La Jolla, California, United States of America, **7** Institute of Neurobiology, Slovak Academy of Sciences, Košice, Slovakia


Neural Induction of Pluripotent Stem Cells







Characterization of cell-surface signatures enables:

- Identification of subpopulations
 - Transplantation
- Isolation of pure populations
 - Arrays
 - Biochemistry
 - In vitro assays and models
- Development of quality control assays for cell preparations
 - Purity assessment
 - Contaminant identification

Cell Surface Marker Screen: Flow Cytometry




CD184⁺/CD44⁻/CD271⁻/CD24⁺ Define a Cell-Surface Signature for the Isolation of NSCs




Sorted NSCs Differentiate to Mixed Cultures of Neurons and Glia

H9 NSCs differentiated for 3 weeks




*HUES-9 NSCs 8 weeks post-
engraftment in rat spinal cord*




Data courtesy of Mike Hefferan and Martin Marsala, UCSD


Isolation of Neurons and Glia by Sorting




Glia:
CD184⁺/CD44⁺



Neurons:
CD184⁻/CD44⁻/CD15^{lo}/CD24⁺



Summary




- Defined cell-surface signatures for NSCs, neurons, and glia
- Signatures enable:
 - ✓ Standardized and robust isolation of hESC-derived neural stem cells
 - ✓ Downstream applications requiring consistent or pure cell populations
- The immunophenotyping principle can be applied in other stem cell fields.


Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells

Nature January 2012, Volume 482, Issue 7384


Mason A. Israel^{1,2}, Shauna H. Yuan^{1,3}, Cedric Bardy⁴, Sol M. Reyna^{1,2}, Yangling Mu⁴, Cheryl Herrera¹, Michael P. Hefferan⁵, Sebastiaan Van Gorp⁶, Kristopher L. Nazor⁷, Francesca S. Boscolo⁸, Christian T. Carson⁹, Louise C. Laurent⁸, Martin Marsala^{5,10}, Fred H. Gage⁴, Anne M. Remes¹¹, Edward H. Koo³ & Lawrence S. B. Goldstein^{1,3}



Cell-Surface Signatures for the Isolation of Neurons



Identification of Cell-Surface Marker Signatures of Neurons



6-Week Neural Induction Culture

Disassociate Cultures

Stain with BD Lyoplate™ Human Cell Surface Marker Screening Panel







Fix

Perm



Stain with Sox1, Sox2, Pax6, and DCX

HTS Flow Cytometry

Analyze cell-surface marker expression of populations defined by intracellular markers







Isolation of Neurons Using CD200 and HLA-A,B,C



Pre-Sort


CD200^{mid}
HLA-A,B,C⁺

CD200^{hi}
HLA-A,B,C⁻



Cell-Surface Signatures for the Isolation of Neurons

*Without IC flow:
Screened 6 different cell cultures*



*With IC flow:
Screened 1 cell culture*

Improved Sorting of Pluripotent Stem Cells





Sorting and Analysis of Pluripotent Stem Cells

- Are sorted hESCs viable?
 - Fong CY, Peh GS, Gauthaman K, Bongso A. Separation of SSEA-4 and TRA-1-68 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). *Stem Cell Rev.* 2009;5:72-80.
 - Nicholas CR, Gaur M, Wang S, Pera RA, Leavitt AD. A method for single-cell sorting and expansion of genetically modified human embryonic stem cells. *Stem Cells Dev.* 2007;16:109-117.
 - Sidhu KS, Tuch BE. Derivation of three clones from human embryonic stem cell lines by FACS sorting and their characterization. *Stem Cells Dev.* 2006;15:61-69.
- Do sorted cells still express markers of pluripotency?
- Are sorted cells capable of further differentiation?
- No commercial, standardized methods for sorting hESCs by flow cytometry.

Sorting and Analysis of Pluripotent Stem Cells


- The ROCK inhibitor, Y-27632, enhances survival of hESCs after single-cell dissociation.
 - Narumiya S, Ishizaki T, Uehata M. Use and properties of Rock-specific inhibitor Y-27632. *Methods Enzymol.* 2000;325:273-284.
 - Watanabe K, Ueno M, Kamiya D, et al. A Rock inhibitor permits survival of dissociated human embryonic stem cells. *Nat Biotechnol.* 2007;681-686.

Sorting Based on Markers for Pluripotency and Differentiation





E





Population	%Parent	%Total
■ All Events	####	100.0
■ All Cells	83.7	83.7
■ DD SSC	89.3	74.8
■ DD FSC	91.9	68.7
■ SSEA-1-	97.6	67.0
■ SSEA-3+TRA-1-81+	83.4	55.9



ROCK Inhibitor Y-27632 Increases Cell Recovery Post Sort



Sorted hESCs Retain Pluripotency



Sorting and Analysis of Pluripotent Stem Cells

The ROCK inhibitor Y-27632 improves recovery of human embryonic stem cells after fluorescence-activated cell sorting with multiple cell surface markers. Nil Emre, Jason G. Vidal, Jeanne Elia, Eric D. O'Connor, Rosanto I. Paramban, Michael P. Hefferan, Roman Navarro, Danielle S. Goldberg, Nissi M. Varki, Martin Marsala, and Christian T. Carson. *PLoS One*, 2010.

- Sorted hESCs are viable and recoverable.
- Recovery of cells is improved by the addition of Y-27632.
- Sorted cells express markers of pluripotency, are able to differentiate, and can maintain a normal karyotype.
- Standardized method for sorting hESCs by flow cytometry.



Enrichment for hiPSCs During Reprogramming

Flow Cytometry and hiPSCs

[PLoS One](#), 2013;8(3):e59867. doi: 10.1371/journal.pone.0059867. Epub 2013 Mar 29.

Improved methods for reprogramming human dermal fibroblasts using fluorescence activated cell sorting.

[Kahler DJ](#), [Ahmad FS](#), [Ritz A](#), [Hua H](#), [Moroziewicz DN](#), [Sproul AA](#), [Dusenberry CR](#), [Shang L](#), [Paull D](#), [Zimmer M](#), [Weiss KA](#), [Egli D](#), [Noggle SA](#).
The New York Stem Cell Foundation, New York, New York, United States of America.

[Sci Rep](#), 2013;3:1179. doi: 10.1038/srep01179. Epub 2013 Jan 31.

Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection.

[Abujarour R](#), [Valamehr B](#), [Robinson M](#), [Rezner B](#), [Vranceanu F](#), [Flynn P](#).
Fate Therapeutics Inc., 3535 General Atomics Court Suite 200, San Diego, CA 92121, USA.

[Sci Rep](#), 2012;2:213. Epub 2012 Jan 6.


A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs.

[Valamehr B](#), [Abujarour R](#), [Robinson M](#), [Le T](#), [Robbins D](#), [Shoemaker D](#), [Flynn P](#).
Fate Therapeutics Inc. , San Diego, CA, USA.


BD Stemflow™ Human Induced Pluripotent Stem Cell Analysis and Sorting Kit

Reprogramming Time Course

Cells at Day 21 Post-Transduction




Cells at Day 35 Post-Transduction




Data courtesy of Peter Flynn and Bob Valamehr, Fate Therapeutics


Sorting Established hiPSC Lines



Day 6 Post-Sort



Day 11 Post-Sort





Data courtesy of David Kahler, New York Stem Cell Foundation

BD Pharmingen™ Cell Sorting Preparation Buffer Set



- Preparation and maintenance of single-cell suspensions for sorting and analysis
- Cell types tested for sorting applications:
 - Human bone marrow
 - T cells
 - Regulatory T cells (Tregs)
 - hESCS
 - NSCs
 - Neurons

End of Sort Viability Comparison: hESCs


Complete Media



Sorting Buffer




Post-Sort Analysis: hESCs



Cells Alone

Sorting Buffer


Complete Media



Monitoring Neural Ectoderm and Endoderm Differentiation from hESCs using Multiparameter Flow Cytometry

BD Stemflow™ Neural Lineage Analysis Kit

Differentiation of hESC-derived NSCs to neurons and glia




BD Stemflow Neural Lineage Analysis Kit

<i>Specificity</i>	<i>Format</i>	<i>Molecule</i>	<i>Neural Cell Population Identified</i>
CD44	FITC	H-CAM	Glial precursors, astrocytes
Ki-67	Alexa Fluor® 488	Proliferation marker	All proliferating cell types
Doublecortin	PE	Neurofilament	Immature neurons
Sox2	PerCP-Cy™5.5	Transcription Factor	NSCs, glial precursors
Sox1	PerCP-Cy5.5	Transcription Factor	NSCs, glial precursors
GFAP	Alexa Fluor® 647	Filament	Mature astrocytes
Nestin	Alexa Fluor® 647	Filament	NSCs, glial precursors
<i>Buffers Included</i>			
BD Cytotfix™ fixation buffer			
BD Phosflow™ perm buffer III			

For Research Use Only. Not for use in diagnostic or therapeutic procedures.


BD Stemflow Neural Lineage Analysis Kit

Differentiation of hESC-derived NSCs to neurons and glia




Endodermal Differentiation from hESCs

hESCs



3 Days
Low FBS, Activin
(D'Amour et al, 2005)

Definitive Endoderm



Goal: To develop quantitative flow cytometric assays to monitor endodermal differentiation


BD Stemflow™ Definitive and Pancreatic Endoderm Analysis Kit

Panel Components

<u>Specificity</u>	<u>Clone</u>	<u>Isotype</u>	<u>Format</u>
Pax-6	O30-1330	mIgG₁, κ	Alexa Fluor® 488
PDX-1	658A5.1.37	mIgG₁, κ	PE
FoxA2	N17-280	mIgG₁, κ	PE
Sox2	O30-678	mIgG₁, κ	PerCP-Cy5.5
Sox17	P7-969	mIgG_{2a}, κ	PerCP-Cy5.5
Nanog	N31-355	mIgG₁, κ	Alexa Fluor® 647

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Monitoring Endodermal Differentiation Using Flow Cytometry



CyT49 hESCs

MSC Characterization using Flow Cytometry

MSC Definition

POSITION PAPER

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

M Dominici¹, K Le Blanc², I Mueller³, I Slaper-Cortenbach⁴, FC Marini⁵, DS Krause⁶, RJ Deans⁷, A Keating⁸, DJ Prockop⁹ and EM Horwitz¹⁰

- *MSCs must be plastic adherent.*
- *MSCs must express CD73, CD105, and CD90 and lack expression of CD45, CD34, CD14, CD11b, CD79a, and CD19.*
- *MSCs must differentiate into osteoblasts, adipocytes, and chondrocytes in vitro.*

MSC Variability

Source:

- Bone marrow
- Adipose tissue
- Umbilical cord

Intra-population heterogeneity:

- Early vs late passage in culture
- Normoxia vs hypoxia
- Serum vs serum free
- Subsets of MSCs with distinct functions and potential

MSC Heterogeneity

Neural Ganglioside GD2 Identifies a Subpopulation of Mesenchymal Stem Cells in Umbilical Cord

Jie Xu¹, WenBin Liao¹, DongSheng Gu¹, Lu Liang¹, Meng Liu¹, WeiTing Du¹, PengXia Liu¹, Lei Zhang¹, ShiHong Lu¹, ChunLan Dong¹, Bin Zhou² and Zhongchao Han¹

The Globoseries Glycosphingolipid SSEA-4 Is a Marker of Bone Marrow-Derived Clonal Multipotent Stromal Cells In Vitro and In Vivo

Michael Rosu-Myles,¹ Jennifer McCully,¹ Joel Fair,² Jelica Mehic,¹ Pablo Menendez,³ Rene Rodriguez,⁴ and Carole Westwood¹

Perivascular support of human hematopoietic stem/progenitor cells


Mirko Corselli, Chee Jia Chin, Chintan Parekh, Arineh Sahaghian, Wenyuan Wang, Shundi Ge, Denis Evseenko, Xiaoyan Wang, Elisa Montelatici, Lorenza Lazzari, Gay M. Crooks and Bruno Péault

Engineering bone tissue substitutes from human induced pluripotent stem cells


Giuseppe Maria de Peppo^a, Iván Marcos-Campos^b, David John Kahler^a, Dana Alsalman^a, Linshan Shang^a, Gordana Vunjak-Novakovic^b, and Darja Marolt^{a,1}

Tra1 60	0.6	0.3	1.1	1.6	1.1	0.7	ALP	75.3	26.3	8.2	11.6	10.6	3.3
SSEA4	18.9	39.4	7.3	55.7	67.7	4.8	CD49a	21.8	12.4	9.5	1.8	1.4	10.4
SSEA1	0.7	0.3	1.0	1.4	1.0	1.0	CD49b	89.1	90.7	71.0	87.2	74.0	11.5
CD14	0.7	0.2	1.0	1.3	1.1	0.8	CD49c	53.1	59.4	90.7	88.3	67.6	47.1
CD31	0.7	0.2	1.2	1.3	1.0	3.3	CD49d	23.8	13.4	37.0	19.9	21.4	55.0
CD34	0.6	0.3	0.9	1.3	1.1	0.9	CD49f	35.7	37.1	54.0	75.2	64.8	34.5
CD45	0.7	0.2	0.9	1.5	1.1	0.9	CD51/61	17.7	7.7	43.7	3.4	7.8	4.9
HLA-A2	72.9	0.2	60.5	45.5	1.1	74.5	CD54	47.4	31.8	66.9	66.7	22.5	16.7
HLA-DM	0.9	0.2	0.9	1.0	1.3	0.6	CD140b	46.2	40.5	51.8	32.1	23.0	0.0
HLA-DR	0.9	0.1	0.8	1.3	1.0	0.7	CD146	15.6	29.1	57.7	67.9	52.1	26.2
HLA-ABC	5.0	1.1	2.7	3.6	1.1	3.6							


BD Stemflow™ Human MSC Analysis Kit




Lin PE




CD90 FITC




CD73 APC



CD105 PerCP-Cy5.5



GD2



GD2

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

The Devil is in the Details: Heterogeneity

Heterogeneity of stem cell cultures is a major challenge

Potential solution:

- **Defined cell-surface signatures for stem cells and their derivatives**
 - BD Lyoplate™ Human Cell Surface Marker Screening Panel
 - BD Lyoplate™ Mouse Cell Surface Marker Screening Panel
- **Robust methods for cell sorting**
 - BD Stemflow™ Neural Sorting Kit
 - BD Stemflow™ Pluripotent Stem Cell Sorting and Analysis Kit
 - BD Stemflow™ Human Induced Pluripotent Stem Cell Analysis and Sorting Kit
 - BD Pharmingen™ Lineage Cocktail 4 (lin 4)
 - ROCK Inhibitor (Y-27632)
 - BD Pharmingen™ Cell Sorting Preparation Buffer Set
- **Quantitative analysis tools for heterogeneous cell cultures**
 - BD Stemflow™ Definitive and Pancreatic Endoderm Analysis Kit
 - BD Stemflow™ Neural Lineage Analysis Kit
 - BD Stemflow™ Human MSC Analysis Kit
 - BD Stemflow™ Human and Mouse Pluripotent Stem Cell Analysis Kit
 - BD Stemflow™ Human Pluripotent Stem Cell Transcription Factor Analysis Kit
 - BD Stemflow™ Mouse Pluripotent Stem Cell Transcription Factor Analysis Kit

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Acknowledgments

BD Research and Development:

Christian Carson
Mirko Corselli
Ravi Hingorani
Amy Hsieh
Jody Martin
Erika O'Donnell
Jurg Rohrer
Jason Vidal
Lissette Wilensky

ViaCyte, Inc.
Mark Moorman

UCSD
Larry Goldstein
Martin Marsala
Eric D. O'Connor

BD Colleagues

Bob Balderas
Trent Colville
Andrea Nguyen
Dennis Sasaki

Fate Therapeutics

Peter Flynn
Bob Valamehr

New York Stem Cell Foundation

David Kahler
Dorota Moroziewicz
Matthew Zimmer



If you have further questions:

Contact your US Reagent Sales Rep
or e-mail: ResearchApplications@bd.com

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Alexa Fluor® is a registered trademark of Life Technologies Corporation.

Cy™ is a trademark of GE Healthcare.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2013 BD

bdbiosciences.com

